Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.53 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211310 | 0.84 | KMT2A (0.69) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3216340 | 0.83 | KMT2A (0.67) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3212017 | 0.81 | KMT2A (0.61) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3203230 | 0.81 | KMT2A (0.64) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL5650231 | 0.80 | RAB9A (0.76) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3208827 | 0.80 | KMT2A (0.69) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3221907 | 0.80 | KMT2A (0.66) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL775030 | 0.79 | MEN1 (0.65) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL1417105 | 0.79 | MEN1 (0.81) | KMT2AMEN1KEAP1NFE2L2CASP3 | |
| SCHEMBL3208977 | 0.79 | MEN1 (0.56) | KMT2AMEN1KEAP1NFE2L2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | claimed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | claimed |
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | Compass Pharmaceuticals LLC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1802606-B1 | ARYLCARBOXAMIDES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071513-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KMT2A 3661/4885MEN1 40/4885KEAP1 202/4885 |
| US-20110178087-A1 | Compositions and Their Use as Anti-Tumor Agents | TP53, VHL, RB1 | KMT2A 3661/4885MEN1 40/4885KEAP1 202/4885 |
| US-20090018145-A1 | Compositions and their use as anti-tumor agents | TP53, VHL, RB1 | KMT2A 3489/4885MEN1 26/4885KEAP1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.